Sana Biotechnology, Inc. SANA
Regular-session close
After hours · Nov 19, 4:18 PM ET
- YTD
- -57.25%
- 1 year
- -48.82%
5D -0.52 (-21.40%)
- Market cap
- 521.36M
- EPS (ttm)
- -0.52
- Shares out
- 299.36M
- Forward P/E
- -6.21
- YTD return
- -57.25%
- 1-year return
- -48.82%
- 50-day average
- 3.61
- 200-day average
- 3.70
- Volume
- 3.99M
- Avg volume
- 3.26M
- Open
- 1.85
- Previous close
- 1.85
- Day's range
- 1.70 – 1.89
- 52-week range
- 1.70 – 5.49
- Beta
- 2.13
- Price target
- 8.43 (+384.4%)
Key statistics
- Enterprise value
- 1.07B
- Price / book
- 6.69
- Free cash flow
- 4.13M
- Total cash
- 160.49M
- Total debt
- 80.94M
- Return on equity
- -152.87%
- Short % of float
- 24.00%
Fundamental scorecard
4 of 25 checks passed on SANA’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.18 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.1469 | -0.22 | -0.07 | -49.76% |
| May 11, 2026 | Mar 31, 2026 | -0.15 | -0.14 | +0.01 | +6.67% |
| Mar 3, 2026 | Dec 31, 2025 | -0.13 | -0.16 | -0.03 | -23.08% |
| Nov 6, 2025 | Sep 30, 2025 | -0.18 | -0.15 | +0.03 | +16.67% |
| Aug 11, 2025 | Jun 30, 2025 | -0.20 | -0.39 | -0.19 | -95.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 2026 | B of A Securities | main | Buy | Buy |
| Apr 14, 2026 | Wedbush | main | Outperform | Outperform |
| Mar 4, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jan 6, 2026 | B of A Securities | main | Buy | Buy |
| Nov 7, 2025 | Wedbush | main | Outperform | Outperform |
| Nov 7, 2025 | HC Wainwright & Co. | main | Buy | Buy |
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sana.com
News
Your note
Sign in to keep a note on SANA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BISHOP HANS EDGAR | Director | Stock Award(Grant) | Jul 5, 2026 | 5,854,800 |
| CASSIDY BERNARD J | General Counsel | Conversion of Exercise of derivative security | Mar 6, 2025 | 112,990 |
| FMR LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | Jan 7, 2025 | 0 |
| HARR STEVE M.D. | Chief Executive Officer | Conversion of Exercise of derivative security | Mar 5, 2026 | 8,960,750 |
| MULLIGAN RICHARD CHARLES PH.D | Director | Sale | Sep 24, 2024 | 2,698,120 |
| WYRICK SUSAN D | Officer | Conversion of Exercise of derivative security | Mar 5, 2026 | 196,196 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 12.50% | 37,429,515 | 129.13M | Jun 29, 2026 |
| Flagship Pioneering LLC | 8.35% | 25,001,856 | 86.26M | Jun 29, 2026 |
| RA Capital Management, L.P. | 6.26% | 18,750,000 | 64.69M | Jun 29, 2026 |
| Blackrock Inc. | 5.57% | 16,675,173 | 57.53M | Jun 29, 2026 |
| State Street Corporation | 3.74% | 11,203,134 | 38.65M | Jun 29, 2026 |
| Canada Pension Plan Investment Board | 3.41% | 10,218,400 | 35.25M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 3.51% | 10,495,617 | 36.21M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.36% | 7,077,517 | 24.42M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.09% | 6,251,644 | 21.57M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.61% | 4,807,959 | 16.59M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.04% | 3,119,059 | 10.76M | Jul 30, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 0.95% | 2,857,700 | 9.86M | Jul 30, 2026 |
